No Data
No Data
Downgrade: Here's How Analysts See Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Performing In The Near Term
The latest analyst coverage could presage a bad day for Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192), with the analysts making across-the-board cuts to their statutory estimates that might l
Dizhe Pharmaceutical (688192.SH): Chairman and others completed an increase in holdings of 6.59 million yuan
Zhitong Finance App News, Dizhe Pharmaceutical (688192.SH) announced that as of May 8, 2024, Dr. Zhang Xiaolin, Chairman and CEO of the company, Mr. Lu Hongbin, Secretary of the Board of Directors and Chief Financial Officer, and Ms. Wu Qingyi, Deputy General Manager and Chief Commercial Officer, have increased their holdings by 1991.88 million shares, accounting for 0.0479% of the company's total share capital, with a total increase of 6.597.42 million yuan. The plan to increase holdings has been completed.
These 4 Measures Indicate That Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Dizhe Pharmaceutical (688192.SH) announced first-quarter results with a net loss of 224 million yuan
Dizhe Pharmaceutical (688192.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved an operating income of 8...
Dizhe Pharmaceutical (688192.SH) announced its 2023 annual results with a net loss of 1.08 billion yuan
Dizhe Pharmaceutical (688192.SH) released its 2023 annual performance report. During the reporting period, the company achieved an operating income of 9...
2024 CSCO guide major update! Schwarzhe was included in the Level I recommendation, and goliximitinib was recommended for the first time, breaking through the bottleneck of treating difficult tumor targets
SHANGHAI, April 27, 2024/PRNewswire/ -- From April 26 to 27, 2024, the Chinese Society of Clinical Oncology (CSCO) guidelines conference was held in Jinan. In the 2024 CSCO diagnosis and treatment guidelines released at this conference, the two original innovative drugs independently developed by Dizhe Pharmaceutical (stock code: 688192.SH), and golisitinib, were both included in the guidelines as recommended drugs. Schwarzhe was recommended by the “CSCO Guidelines for the Diagnosis and Treatment of Non-small Cell Lung Cancer (2024 Edition)” at Level I, which targets experience in this guideline
No Data